AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Sees Large Increase in Short Interest

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totaling 2,765,187 shares, a growth of 382.9% from the August 31st total of 572,582 shares. Based on an average daily volume of 11,020,474 shares, the short-interest ratio is presently 0.3 days. Currently, 9.2% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets cut their price target on shares of AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, June 1st. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

AIM ImmunoTech Trading Down 6.5%

NYSEAMERICAN AIM traded down $0.01 on Friday, hitting $0.19. 1,876,290 shares of the company were exchanged, compared to its average volume of 12,515,635. AIM ImmunoTech has a 1-year low of $0.19 and a 1-year high of $2.88. The firm has a 50 day moving average of $0.24 and a two-hundred day moving average of $0.40. The company has a market cap of $5.79 million, a P/E ratio of -0.06 and a beta of 1.19.

AIM ImmunoTech (NYSEAMERICAN:AIM) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.43) earnings per share for the quarter. The company had revenue of $0.03 million for the quarter. Research analysts anticipate that AIM ImmunoTech will post -0.78 EPS for the current fiscal year.

About AIM ImmunoTech

AIM ImmunoTech Inc is a biotechnology company focused on developing and commercializing immunomodulatory therapies for cancer, viral diseases and disorders involving the immune system. The company’s lead product candidate is Ampligen (rintatolimod), an investigational double-stranded RNA therapeutic designed to stimulate immune responses and is being studied in several disease settings.

AIM also owns Alferon N Injection, an interferon alfa-n3 product approved in the United States for the treatment of refractory or recurring external genital warts in adults.